Gentex clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Gentex Corporation
GNTX · Nasdaq · USD · Market cap $3.9B · 6,398 employees
Gentex Corporation designs, develops, manufactures, markets, and supplies digital vision, connected car, dimmable glass, fire protection technologies, audio products, medical devices, and consumer electronics.
Not yet scoredPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price19.17 USD at the 19 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 19 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 6.64)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $28.73 to $38.66, base estimate $30.00 (screen dated 2026-11-19).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 6.64, read 2026-11-19
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Gentex Corporation holds its Distribution at $19.17. Elevated stress, defensive posture warranted, held for 7 days.
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 7 days |
| Price at the screen | $19.17 |
| Valuation | 10.14 trailing · 8.88 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.85 |
Five Screens: GNTX's Results
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.13% | Below 33% | Pass |
| Interest-bearing cash | 0.18% | Below 33% | Pass |
| Receivables | 17.56% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadThe Read, in Plain English
Gentex clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Gentex clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 36% discount to our $30.00 fair value.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 36.1% discount to the base estimate.
Third-party analyst targets: 9 covering, consensus Hold. The average target sits +25% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $30.00, with a range of $28.73 to $38.66, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Forward P/E | 8.9xvery cheap relative to earnings |
| Trailing P/E | 10.1xreasonably valued |
| EPS, trailing | 1.87 |
| EPS, forward | 2.14 |
| Revenue growth | -1.1%revenue is shrinking |
| Profit margin | 15.1%healthy profit margins |
| Return on equity | 15.9%a solid return on shareholder capital |
| FCF yield | 8.47% |
| Dividend yield | 1.99% |
| Debt to equity | 0.30minimal debt: a conservative balance sheet |
| Current ratio | 2.92comfortably covers its short-term bills |
| Beta | 0.85steadier than the market |
| Short interest, float | 0.09% |
| 52-week range | 18.89 - 26.48 |
| Market cap | $3.9B |
| Employees | 6,398 |
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. Since the last review it its composite score eased.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Gentex (GNTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Yahoo Finance · 7d ago
- 5 Best Debt Free Dividend Stocks to Buy Right Now Yahoo Finance · 15d ago
- The Gentex Sema Booth to Feature Custom Car Reveals by Ringbrothers and Classic Car Studio Yahoo Finance · 17d ago
- Gentex Eyes $2B Electronics Opportunity as It Expands Beyond Auto Mirrors Yahoo Finance · 17d ago
- Gentex: 3 Key Takeaways for Long-Term Investors Yahoo Finance · 23d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.20 | +7.1% | · | $1,071 | +7.1% |
| 2 months | $21.99 | +13.0% | · | $1,130 | +13.0% |
| 3 months | $21.19 | +17.3% | $0.12 | $1,178 | +17.8% |
| 6 months | $23.47 | +5.9% | $0.24 | $1,069 | +6.9% |
| 1 year | $21.81 | +13.9% | $0.48 | $1,161 | +16.1% |
| 2 years | $32.81 | -24.3% | $0.96 | $786 | -21.4% |
| 3 years | $26.18 | -5.1% | $1.44 | $1,004 | +0.4% |
| 5 years | $31.41 | -20.9% | $2.40 | $867 | -13.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GNTX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.